Risk factors

General Fusion Group has no operating history or revenue as a blank check company seeking an initial business combination. Risks focus on shareholder redemption rights, trust account security, potential conflicts of interest, and regulatory compliance under the Investment Company Act and SEC SPAC rules.

New Clean Air Act and methane regulations in Colorado and New Mexico add compliance costs. Tax law interpretations and changes create new operating liabilities. The EPA revoked its greenhouse gas Endangerment Finding in February 2026.

Great Southern Bancorp added new risks covering credit loss qualitative factors, AI governance, and evolving ESG expectations. Brokered deposits decreased to $663.4 million from $772.1 million. Insider and family stock ownership percentages and share counts were updated.

No risks were added or removed this year.

Added focus on technological disruption, generative AI risks, and digital asset disintermediation. Labor costs and retention risks expanded for remote work. Voting trust ownership stake updated to 54.8%.

The company added risks concerning share purchases by insiders and potential Nasdaq delisting consequences after a business combination.

Independent Bank Corp added major risks regarding AI adoption, uninsured deposits, commercial real estate concentrations, and overdraft fee litigation.

The company added substantial risk disclosures regarding artificial intelligence deployment, client payment defaults and related litigation, and international trade policy changes.

Immuneering updated product references from IMM-1-104 and IMM-6-415 to atebimetinib and disclosed a reduction in full-time employees to 53.

Merger activities dominate the new disclosures, highlighting transaction risks and regulatory closing conditions.

IRADIMED added risks concerning macroeconomic instability and compliance controls. The IRS closed its 2021 tax return review with no changes. Founder Roger Susi remains critical to product development and institutional knowledge.

Company is a clinical-stage biotechnology firm reliant on lead program JADE101 and external capital raising. Risk disclosures reflect transition to public company status, clinical trial execution, and intellectual property protection.